


 CrossMark  
 click for updates
Cite this: *RSC Adv.*, 2016, 6, 2671

# TBAI/TBHP-catalyzed [3 + 2]cycloaddition/oxidation/aromatization cascade and online ESI-MS mechanistic studies: synthesis of pyrrolo[2,1-*a*]isoquinolines and indolizino[8,7-*b*]indoles†

 Shalini Nekkanti,<sup>a</sup> Niggula Praveen Kumar,<sup>a</sup> Pankaj Sharma,<sup>a</sup> Ahmed Kamal,<sup>ab</sup> Fabiane M. Nachtigall,<sup>c</sup> Oscar Forero-Doria,<sup>d</sup> Leonardo S. Santos<sup>\*cd</sup> and Nagula Shankaraiah<sup>\*a</sup>

A facile [3 + 2]cycloaddition/oxidation/aromatization cascade reaction for the synthesis of pyrrolo[2,1-*a*]isoquinolines and indolizino[8,7-*b*]indoles has been developed. This tandem approach was accomplished by employing *tert*-butyl hydroperoxide (TBHP) as the environmentally benign stoichiometric oxidant, with the catalysis of non-toxic tetrabutylammonium iodide (TBAI) and isopropanol as the green solvent. Gratifyingly, this protocol is highly versatile, as the construction of polycyclics could be tailored by readily available dipolarophiles. Only a catalytic amount of TBAI was required, as the hypervalent electrophilic iodine species (IOH) can be recovered *in situ* by oxidation with TBHP. Furthermore, for the first time, the mechanistic aspects and the putative intermediates associated with this cascade have been intercepted and characterized by online monitoring of the reaction by using ESI-MS/MS.

Received 20th November 2015

Accepted 16th December 2015

DOI: 10.1039/c5ra24629f

www.rsc.org/advances

## Introduction

The pyrrole ring is a common motif in numerous bioactive alkaloids and pharmaceuticals. The pyrrolo[2,1-*a*]isoquinoline core in the marine lamellarin alkaloids is responsible for their wide spectrum of biological activities. For instance, lamellarin D (A), is a potent inhibitor of human topoisomerase I and lamellarin  $\alpha$  20-sulfate (B) is an inhibitor of HIV integrase (Fig. 1).<sup>1</sup> The indolizino[8,7-*b*]indole core present in  $\beta$ -carboline alkaloids such as harmicine (C) and fascaplysin (D, Fig. 1) has significant biological and pharmaceutical relevance.<sup>2</sup> Despite some elegant syntheses of pyrrolo[2,1-*a*]isoquinolines<sup>3</sup> and indolizino[8,7-*b*]indoles<sup>4</sup> through [3 + 2]cycloadditions, the (hypo)iodite catalyzed green protocol has not yet been explored.

In recent times, the tetrabutylammonium iodide (TBAI)/*tert*-butyl hydroperoxide (TBHP) catalytic system has received unique attention due to its high efficiency, simple operation,

nontoxicity, inexpensiveness, and eco-friendliness.<sup>5</sup> In continuation of our earlier efforts in the field of biologically relevant  $\beta$ -carbolines and their novel approaches,<sup>6</sup> we report the first application of the green TBAI/TBHP catalysis in the [3 + 2] cycloaddition/oxidation/aromatization cascade reaction for the synthesis of pyrrolo[2,1-*a*]isoquinolines and indolizino[8,7-*b*]indoles. Furthermore, for the first time, the reaction mechanism and the intermediates associated with [3 + 2] cycloaddition/oxidation/aromatization cascade have been intercepted and characterized, by online monitoring of the reaction by employing ESI-MS/MS.




Fig. 1 Representative natural lamellarin (A, B) and indolizino[8,7-*b*]indole (C, D) alkaloids.

<sup>a</sup>Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500 037, India. E-mail: shankar.niperhyd@gov.in

<sup>b</sup>Medicinal Chemistry & Pharmacology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, India

<sup>c</sup>Fraunhofer Chile Research Foundation-Center System Biotechnology, FCR-CSB, Nanobiotechnology Division at University of Talca, P.O. Box 747, Talca, Chile

<sup>d</sup>Laboratory of Asymmetric Synthesis, Chemistry Institute of Natural Resources, University of Talca, P.O. Box 747, Talca, Chile. E-mail: lssantos@utalca.cl

† Electronic supplementary information (ESI) available: <sup>1</sup>H and <sup>13</sup>C NMR. See DOI: 10.1039/c5ra24629f

## Results and discussion


The initial investigations were focused on the feasibility of the reaction between ethyl 2-(3,4-dihydroisoquinolin-2(1*H*)-yl)acetate (**1a**) and *N*-phenylmaleimide (**2a**). Optimization of the reaction conditions towards 1,3-dipoles and electron-deficient dipolarophiles were illustrated in Table 1. To our delight, the proposed reaction between **1a** and **2a** does indeed occur in the presence of TBAI (10 mol%) and 70% aqueous TBHP (3 equiv.) in DMF to afford the product **3a** in 86% yield (entry 1, Table 1). Encouraged by this result, we then attempted to determine the ideal solvent for this transformation. The desired product **3a** was obtained in all the tested solvents (entries 1–6), the highest yield of 95% was observed in both acetonitrile and isopropanol (entry 2, and 5, Table 1), and then we have chosen to proceed with isopropanol as it is a green solvent. The reaction did not proceed efficiently at room temperature (entry 7, Table 1) and a minimum temperature of 80 °C was found to be crucial.

The yield of **3a** was not increased much when the amount of TBAI was increased up to 20 mol% (entry 8, Table 1) or when the amount of 70% aqueous TBHP was increased to 5 equiv. (entry 9, Table 1). However, when the amount of TBAI was decreased to 5 mol%, **3a** was obtained in 72% yield (entry 10, Table 1). This supports the catalytic efficiency of the TBAI/TBHP oxidation system even at low concentration. Further, when other oxidants such as 35% aqueous H<sub>2</sub>O<sub>2</sub>, oxone and mCPBA were used

instead of 70% aqueous TBHP, we obtained **3a** in lower yields (entries 11–13, Table 1). Under the same reaction conditions, TBAB can also catalyze this transformation to give **3a** in only 77% yield (entry 14, Table 1). Finally, the best yield of **3a** (95%) was obtained from the reaction of **1a** (1.5 mmol), **2a** (1 mmol), TBAI (10 mol%), and 70% aqueous TBHP (3 equiv.) in isopropanol (5 mL) at 80 °C for 6 h (entry 5, Table 1).

With the optimal reaction conditions established, we then explored the substrate scope of this cascade reaction to construct pyrrolo[2,1-*a*]isoquinolines. As highlighted in Table 2, 1,4-naphthoquinone and a variety of *N*-substituted maleimides (**2a–d**) can react efficiently with **1a–c** to give the corresponding products in good to excellent yields upon isolation. Encouraged by these results, we further examined the scope of structural variation in tetrahydroisoquinoline esters (methyl and *tert*-butyl) and allowed them to react with the dipolarophiles, without loss in the reaction efficiency. As shown, the reaction proceeded smoothly with all *N*-substituted maleimides regardless of bearing electron-neutral (phenyl), donating (*p*-methoxy phenyl) or with-drawing groups (*p*-fluoro phenyl). Among the tetrahydroisoquinoline esters, the reactivity was found to be in the order ethyl > methyl > *tert*-butyl. On the other hand, among the dipolarophiles, 1,4-naphthoquinone gave the best yields of pyrrolo[2,1-*a*]isoquinolines (**3c**, **3g** and **3j**; 96%, 94%, and 77%).


Table 1 Optimization of the reaction conditions<sup>a</sup>



Entry	Catalyst	Oxidant	Solvent	Yield <sup>b</sup> (%)
1	TBAI	TBHP	DMF	86
2	TBAI	TBHP	CH <sub>3</sub> CN	95
3	TBAI	TBHP	Toluene	42
4	TBAI	TBHP	1,4-Dioxane	59
5	TBAI	TBHP	Isopropanol	95
6	TBAI	TBHP	1-Butanol	81
7 <sup>c</sup>	TBAI	TBHP	Isopropanol	nd <sup>d</sup>
8 <sup>e</sup>	TBAI	TBHP	Isopropanol	96
9 <sup>f</sup>	TBAI	TBHP	Isopropanol	96
10 <sup>g</sup>	TBAI	TBHP	Isopropanol	72
11	TBAI	Oxone	Isopropanol	69
12 <sup>h</sup>	TBAI	H <sub>2</sub> O <sub>2</sub>	Isopropanol	83
13	TBAI	mCPBA	Isopropanol	65
14	TBAB	TBHP	Isopropanol	77

<sup>a</sup> Reaction conditions: **1a** (1.5 mmol), **2a** (1 mmol), catalyst (10 mol%), oxidant (3 equiv.), solvent (5.0 mL), 80 °C, 6 h. <sup>b</sup> Isolated yield. <sup>c</sup> At room temperature. <sup>d</sup> n.d. = not detected. <sup>e</sup> The amount of TBAI was increased to 20 mol%. <sup>f</sup> The amount of 70% aqueous TBHP was increased to 5 equiv. <sup>g</sup> The amount of TBAI was decreased to 5 mol%. <sup>h</sup> 35% aqueous H<sub>2</sub>O<sub>2</sub> was used.

Table 2 [3 + 2]Cycloaddition/oxidation/aromatization cascade reaction from **1** and **2**<sup>a</sup>



<sup>a</sup> Reaction conditions: **1** (1.5 mmol), **2** (1 mmol), TBHP 70 wt% in water (3 equiv.), TBAI (10 mol%), isopropanol (5 mL), 80 °C, 6 h. <sup>b</sup> 35% aqueous H<sub>2</sub>O<sub>2</sub> (3 equiv.) was used as oxidant.






Fig. 2 (a) Online ESI-MS screening of the reaction of the dipolarophile **2a** (1.0 mmol), tetrahydroisoquinoline acetate **1a** (1.5 mmol), TBAI (10 mol%), 70% aqueous TBHP (3.0 equiv.), and TBHP in isopropanol (25.0 mL) under an air atmosphere after 1:50 min. (b) Online ESI-MS spectra of the reaction after 2 h of experiments.

pressurized sample infusion (PSI) methodology,<sup>10</sup> which allows us to screen the reaction solutions in real-time for 6 h at 80 °C under stirring. Initially, after 20 s to 2 h of reaction, three cationic species directly related to the proposed catalytic cycle can be observed (Scheme 1), which are detected as major ions (Fig. 2a):  $[1a + H]^+$  of  $m/z$  220, the main iminium intermediate  $[B]^+$  of  $m/z$  218, and  $[Bu_4N]^+$  of  $m/z$  242. Furthermore, the proton-bond dimer of **1a** is also observed as  $[1a + H + 1a]^+$  ( $m/z$  439). Following the reaction by ESI-MS in the negative ion-mode gives a clean spectrum of iodide ion of  $m/z$  127. No other anionic species are observed in the ESI(-)-MS spectra. After 2 h of reaction, a proton-bond dimer of  $m/z$  437 is observed (Fig. 2b), which was a key transient intermediate for the formation of zwitterionic species **C** in solution. The characterization of this species was performed by ESI-MS/MS experiments, which afforded as expected, two main fragment pathways producing intermediate **D** of  $m/z$  220, and iminium ion  $[B]^+$  of  $m/z$  218. Moreover, the intermediate  $[F + H]^+$  of  $m/z$  391 (Fig. 2b) can be also observed in Fig. 2a. The fragmentation of the ion  $[F + H]^+$  of  $m/z$  391 by CID experiments afforded the ion  $[F + H - CO]^+$  of  $m/z$  363, and  $[F + H - 2 \times CO - H_2O]^+$  of  $m/z$  317. Furthermore, the aromatization process can also be observed online as depicted in Fig. 2b, as the ion of  $m/z$  389 starts to be produced and giving the final product of  $m/z$  387  $[3a + H]^+$  that is the protonated form of **3a**.

## Experimental section

### General information

All solvents were purified and dried using standard methods prior to use. Commercially available reagents were used without further purification. <sup>1</sup>H NMR spectra were recorded on an NMR

instrument operated at 500 MHz. Chemical shifts are reported in ppm with the solvent resonance as the internal standard (CDCl<sub>3</sub>;  $\delta$  7.26 ppm). <sup>13</sup>C NMR spectra were recorded on an NMR instrument operated at 125 MHz with complete proton decoupling. Chemical shifts are reported in ppm with the solvent resonance as the internal standard (CDCl<sub>3</sub>;  $\delta$  77.16 ppm). The following abbreviations were used for <sup>1</sup>H NMR spectra to indicate the signal multiplicity: s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). MS and HRMS were measured in EI or ESI<sup>+</sup> mode and the mass analyzer of the HRMS was TOF. Thin layer chromatography was performed on pre-coated glass back plates and visualized with UV light at 254 nm.

Online monitoring experiments were carried out by overpressure in a Schlenk flask held at 2.0 psi (air) throughout the reaction and the temperature was controlled by an oil bath through and magnetic stirrer placed in the flask. The reaction mixture was transferred to ESI ion-source directly through PEEK tubing (200 mm in length, i.d. 0.055 mm). Mass spectra were recorded by Electrospray Ionization Mass Spectrometry (ESI-MS) and tandem mass (ESI-MS/MS), and the online mechanistic studies were carried out by using ESI(+)-MS(/MS) in a Bruker Daltonics AmaZon SLion trap equipment.

**Typical reaction procedure.** The dipolarophiles **2a–d** (1.0 mmol) were added to a mixture of a tetrahydroisoquinoline acetates **1a–c** or tetrahydro- $\beta$ -carboline acetates **4a–c** (1.5 mmol), TBAI (10 mol%), 70% aqueous TBHP (3 equiv.), and TBHP in isopropanol (5.0 mL) under an air atmosphere. The solution was stirred for 6 h at 80 °C. The crude mixture was filtered and the precipitate washed with ethyl acetate followed by recrystallization from chloroform to obtain the desired products **3a–j** and **5a–f**.

**Ethyl 9,11-dioxo-10-phenyl-6,9,10,11-tetrahydro-5H-pyrrolo[3',4':3,4]pyrrolo[2,1-*a*]isoquinoline-8-carboxylate (3a).** White solid (366 mg, 95%); m.p. 190–191 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.59 (d,  $J$  = 7.3 Hz, 1H), 7.48 (t,  $J$  = 7.7 Hz, 2H), 7.41–7.37 (m, 5H), 7.29 (d,  $J$  = 7.1 Hz, 1H), 4.78 (t,  $J$  = 6.8 Hz, 2H), 4.45–4.42 (m, 2H), 3.18 (t,  $J$  = 6.7 Hz, 2H), 1.46 (t,  $J$  = 7.0 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  = 163.0, 161.5, 159.6, 133.4, 132.5, 132.3, 130.3, 128.9, 127.9, 127.9, 127.7, 127.6, 127.1, 125.5, 125.2, 118.6, 116.2, 61.6, 43.3, 28.3, 14.7; HRMS (ESI-TOF)  $m/z$  calculated for C<sub>23</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>  $[M + H]^+$  387.1344, found 387.1350.

**Ethyl 9,11-dioxo-10-(4-fluorophenyl)-6,9,10,11-tetrahydro-5H-pyrrolo[3',4':3,4] pyrrolo[2,1-*a*] isoquinoline-8-carboxylate (3b).** White solid (383 mg, 95%); m.p. 247–248 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.56 (d,  $J$  = 7.0 Hz, 1H), 7.43–7.36 (m, 4H), 7.30 (d,  $J$  = 7.0 Hz, 1H), 7.17 (t,  $J$  = 8.3 Hz, 2H), 4.77 (t,  $J$  = 6.8 Hz, 2H), 4.45–4.41 (m, 2H), 3.18 (t,  $J$  = 6.8 Hz, 2H), 1.46 (t,  $J$  = 7.17 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  = 163.0, 161.5, 159.5, 133.5, 132.4, 130.4, 128.9, 128.8, 128.0, 127.9, 127.6, 125.4, 125.0, 118.7, 115.9, 61.6, 43.4, 28.3, 14.1; HRMS (ESI-TOF)  $m/z$  calculated for C<sub>23</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>4</sub>  $[M + H]^+$  405.1250, found 405.1252.

**Ethyl 9,14-dioxo-5,6,9,14-tetrahydrobenzo[5,6]isoindolo[1,2-*a*]isoquinoline-8-carboxylate (3c).** Yellow solid (356 mg, 96%); m.p. 144–145 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 9.01 (d,  $J$  = 7.9 Hz, 1H), 8.31 (d,  $J$  = 7.3 Hz, 1H), 8.22 (d,  $J$  = 7.3 Hz, 1H),

7.74–7.68 (m, 2H), 7.46 (t,  $J = 7.6$  Hz, 1H), 7.38 (t,  $J = 7.3$  Hz, 1H), 7.28 (d,  $J = 7.4$  Hz, 1H), 4.57–4.54 (m, 2H), 4.30 (t,  $J = 6.5$  Hz, 2H), 3.11 (t,  $J = 6.5$  Hz, 2H), 1.50 (t,  $J = 7.1$  Hz, 3H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 179.7, 179.4, 161.4, 135.6, 135.6, 134.7, 133.6, 133.2, 132.9, 130.0, 128.8, 127.4, 127.3, 127.2, 126.6, 126.3, 126.0, 123.2, 117.4, 62.4, 43.1, 29.1, 14.0$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{23}\text{H}_{17}\text{NO}_4$   $[\text{M} + \text{H}]^+$  372.1235, found 372.1238.

**Methyl 9,11-dioxo-10-phenyl-6,9,10,11-tetrahydro-5H-pyrrolo [3',4':3,4]pyrrolo[2,1-*a*]isoquinoline-8-carboxylate (3d).** Orange solid (342 mg, 92%); m.p. 217–218 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.59$  (d,  $J = 8.2$  Hz, 1H), 7.49 (t,  $J = 7.7$  Hz, 2H), 7.42–7.36 (m, 5H), 7.30 (d,  $J = 6.8$  Hz, 1H), 4.79 (t,  $J = 6.7$  Hz, 2H), 3.98 (s, 3H), 3.20 (t,  $J = 6.8$  Hz, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 162.9, 161.6, 160.0, 133.6, 132.3, 130.3, 128.8, 128.0, 127.9, 127.7, 127.6, 127.0, 125.4, 125.3, 118.1, 116.2, 52.3, 43.4, 28.3$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{22}\text{H}_{16}\text{N}_2\text{O}_4$   $[\text{M} + \text{H}]^+$  373.1188, found 373.1187.

**Methyl 9,11-dioxo-10-(4-fluorophenyl)-6,9,10,11-tetrahydro-5H-pyrrolo [3',4':3,4] pyrrolo[2,1-*a*] isoquinoline-8-carboxylate (3e).** Orange solid (362 mg, 93%); m.p. 226–227 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.56$  (d,  $J = 7.4$  Hz, 1H), 7.43–7.38 (m, 4H), 7.30 (d,  $J = 6.8$  Hz, 1H), 7.16 (t,  $J = 9.1$  Hz, 2H), 4.78 (t,  $J = 6.7$  Hz, 2H), 3.99 (s, 3H), 3.19 (t,  $J = 6.8$  Hz, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 162.9, 161.5, 159.9, 133.7, 132.4, 130.4, 128.8, 128.7, 128.0, 127.9, 127.6, 125.4, 125.1, 118.2, 115.8, 115.7, 52.3, 43.4, 28.3$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{22}\text{H}_{15}\text{FN}_2\text{O}_4$   $[\text{M} + \text{H}]^+$  391.1094, found 391.1089.

**Methyl 9,11-dioxo-10-(4-methoxyphenyl)-6,9,10,11-tetrahydro-5H-pyrrolo [3',4':3,4] pyrrolo[2,1-*a*] isoquinoline-8-carboxylate (3f).** White solid (333 mg, 83%); m.p. 192–193 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.58$  (d,  $J = 7.3$  Hz, 1H), 7.42–7.37 (m, 2H), 7.29 (t,  $J = 8.8$  Hz, 3H), 7.0 (d,  $J = 8.8$  Hz, 2H), 4.77 (t,  $J = 7.0$  Hz, 2H), 3.98 (s, 3H), 3.84 (s, 3H), 3.18 (t,  $J = 6.8$  Hz, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 163.2, 161.9, 160.1, 158.9, 133.5, 132.3, 130.3, 128.3, 128.0, 127.9, 127.6, 125.5, 125.4, 125.2, 118.0, 116.3, 114.2, 55.4, 52.2, 43.4, 28.3$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{23}\text{H}_{18}\text{N}_2\text{O}_5$   $[\text{M} + \text{H}]^+$  403.1294, found 403.1301.

**Methyl 9,14-dioxo-5,6,9,14-tetrahydrobenzo[5,6]isoindolo[1,2-*a*]isoquinoline-8-carboxylate (3g).** Orange solid (335 mg, 94%); m.p. 205–206 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 9.0$  (d,  $J = 7.7$  Hz, 1H), 8.31 (d,  $J = 8.6$  Hz, 1H), 8.22 (d,  $J = 8.6$  Hz, 1H), 7.73–7.70 (m, 2H), 7.46 (t,  $J = 7.6$  Hz, 1H), 7.39 (t,  $J = 7.3$  Hz, 1H), 7.29 (d,  $J = 7.4$  Hz, 1H), 4.30 (t,  $J = 6.5$  Hz, 2H), 4.07 (s, 3H), 3.11 (t,  $J = 6.5$  Hz, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 179.6, 179.6, 161.8, 135.8, 135.6, 134.6, 133.6, 133.3, 133.0, 130.1, 128.8, 127.4, 127.4, 127.2, 126.6, 126.3, 125.4, 123.4, 117.5, 53.1, 43.2, 29.1$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{22}\text{H}_{15}\text{NO}_4$   $[\text{M} + \text{H}]^+$  358.1079, found 358.1076.

***tert*-Butyl 9,11-dioxo-10-phenyl-6,9,10,11-tetrahydro-5H-pyrrolo[3',4':3,4]pyrrolo[2,1-*a*]isoquinoline-8-carboxylate (3h).** Orange solid (302 mg, 73%); m.p. 234–235 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.59$  (d,  $J = 7.3$  Hz, 1H), 7.48 (t,  $J = 7.9$  Hz, 2H), 7.40–7.35 (m, 5H), 7.29 (d,  $J = 7.1$  Hz, 1H), 4.75 (t,  $J = 6.8$  Hz, 2H), 3.17 (t,  $J = 6.7$  Hz, 2H), 1.66 (s, 9H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 163.2, 161.5, 158.9, 133.0, 132.6, 132.3, 130.1, 128.9, 127.9, 127.9, 127.7, 127.5, 127.2, 125.6, 124.6, 120.1, 116.0, 83.4, 43.2, 28.4, 28.2$ ; HRMS (ESI-

TOF)  $m/z$  calculated for  $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_4$   $[\text{M} + \text{H}]^+$  415.1657, found 415.1660.

***tert*-Butyl 9,11-dioxo-10-(4-fluorophenyl)-6,9,10,11-tetrahydro-5H-pyrrolo [3',4':3,4] pyrrolo[2,1-*a*] isoquinoline-8-carboxylate (3i).** Yellow solid (336 mg, 78%); m.p. 209–210 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.56$  (d,  $J = 7.1$  Hz, 1H), 7.42–7.37 (m, 4H), 7.29 (d,  $J = 7.1$  Hz, 1H), 7.16 (t,  $J = 8.5$  Hz, 2H), 4.75 (t,  $J = 6.8$  Hz, 2H), 3.17 (t,  $J = 6.7$  Hz, 2H), 1.65 (s, 9H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 163.1, 161.5, 158.8, 133.1, 132.4, 130.2, 129.0, 128.9, 128.5, 128.5, 127.9, 127.8, 125.5, 124.4, 120.3, 115.9, 115.7, 83.4, 43.2, 28.3, 28.2$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{25}\text{H}_{21}\text{FN}_2\text{O}_4$   $[\text{M} + \text{H}]^+$  433.1558, found 433.1563.

***tert*-Butyl 9,14-dioxo-5,6,9,14-tetrahydrobenzo[5,6]isoindolo [1,2-*a*]isoquinoline-8-carboxylate (3j).** Orange solid (234 mg, 76%); m.p. 170–171 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 9.02$  (d,  $J = 7.7$  Hz, 1H), 8.31 (d,  $J = 6.8$  Hz, 1H), 8.23 (d,  $J = 6.1$  Hz, 1H), 7.73–7.70 (m, 2H), 7.45 (t,  $J = 7.4$  Hz, 1H), 7.38 (t,  $J = 7.1$  Hz, 1H), 7.28 (d,  $J = 7.4$  Hz, 1H), 4.27 (t,  $J = 6.4$  Hz, 2H), 3.11 (t,  $J = 6.4$  Hz, 2H), 1.68 (s, 9H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 179.8, 179.3, 160.5, 135.7, 135.0, 134.8, 133.5, 133.1, 132.8, 129.9, 128.7, 127.7, 127.4, 127.2, 126.5, 122.4, 117.1, 84.1, 43.0, 29.1, 28.0$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{25}\text{H}_{21}\text{NO}_4$   $[\text{M} + \text{H}]^+$  400.1548, found 400.1546.

**Methyl 9,14-dioxo-5,9,14,15-tetrahydro-6H-naphtho[2',3':1,2]indolizino[8,7-*b*]indole-8-carboxylate (5a).** Red solid, yield (348 mg, 88%); m.p. 180–181 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 11.25$  (s, 1H), 8.27 (d,  $J = 7.1$  Hz, 1H), 8.20 (d,  $J = 7.0$  Hz, 1H), 7.73–7.68 (m, 2H), 7.57 (d,  $J = 7.9$  Hz, 1H), 7.52 (d,  $J = 8.0$  Hz, 1H), 7.30 (t,  $J = 7.4$  Hz, 1H), 7.16 (t,  $J = 7.3$  Hz, 1H), 4.53 (t,  $J = 7.4$  Hz, 2H), 4.08 (s, 3H), 3.29 (t,  $J = 7.3$  Hz, 2H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 180.4, 178.6, 161.4, 136.5, 135.5, 134.5, 133.4, 133.1, 131.9, 127.2, 126.6, 126.4, 125.5, 124.8, 124.3, 122.4, 120.4, 119.0, 115.5, 112.4, 110.9, 53.0, 44.6, 20.4$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{24}\text{H}_{16}\text{N}_2\text{O}_4$   $[\text{M} + \text{H}]^+$  397.1188, found: 397.1185.

**Ethyl 9,14-dioxo-5,9,14,15-tetrahydro-6H-naphtho[2',3':1,2]indolizino [8,7-*b*]indole-8-carboxylate (5b).** Red solid (377 mg, 92%); m.p. 208–209 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 11.28$  (s, 1H), 8.29–8.28 (m, 1H), 8.24–8.22 (m, 1H), 7.74–7.69 (m, 2H), 7.58 (d,  $J = 7.9$  Hz, 1H), 7.52 (d,  $J = 8.2$  Hz, 1H), 7.30 (t,  $J = 8.0$  Hz, 1H), 7.16 (t,  $J = 7.9$  Hz, 1H), 4.58–4.52 (m, 4H), 3.30 (t,  $J = 7.6$  Hz, 2H), 1.52 (t,  $J = 7.1$  Hz, 3H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta = 180.4, 178.4, 161.0, 136.5, 135.5, 134.5, 133.3, 133.0, 131.7, 127.1, 127.0, 126.6, 125.5, 124.8, 124.3, 122.1, 120.3, 118.9, 115.4, 112.3, 110.7, 62.4, 44.5, 20.3, 14.0$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{25}\text{H}_{18}\text{N}_2\text{O}_4$   $[\text{M} + \text{H}]^+$  411.1344, found: 411.1334.

**Ethyl 2-phenyl-1,3-dioxo-1,2,3,6,7,12-hexahydropyrrolo [3',4':1,2]indolizino[8,7-*b*]indole-4-carboxylate (5c).** Orange solid (293 mg, 69%); m.p. 269–270 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3 + \text{DMSO}-d_6$ ):  $\delta = 9.37$  (s, 1H), 7.51 (d,  $J = 7.9$  Hz, 1H), 7.40 (t,  $J = 8.0$  Hz, 3H), 7.32–7.29 (m, 3H), 7.19 (t,  $J = 7.3$  Hz, 1H), 7.08 (t,  $J = 7.6$  Hz, 1H), 4.79 (t,  $J = 7.4$  Hz, 2H), 4.36–4.32 (m, 2H), 3.24 (t,  $J = 7.3$  Hz, 2H), 1.37 (t,  $J = 7.0$  Hz, 3H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3 + \text{DMSO}-d_6$ ):  $\delta = 162.5, 160.7, 158.6, 137.1, 131.9, 128.1, 127.0, 126.5, 126.2, 124.8, 123.7, 123.5, 123.3, 119.9, 119.3, 118.6, 113.1, 111.6, 110.6, 60.8, 44.1, 20.1, 13.5$ ; HRMS (ESI-TOF)  $m/z$  calculated for  $\text{C}_{25}\text{H}_{19}\text{N}_3\text{O}_4$   $[\text{M} + \text{H}]^+$  426.1453, found: 426.1450.

**Ethyl 2-(4-methoxy)phenyl-1,3-dioxo-1,2,3,6,7,12-hexahydropyrrolo[3',4':1,2]indolizino[8,7-b]indole-4-carboxylate (5d).** Yellow solid (304 mg, 67%); m.p. 202–203 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.06 (s, 1H), 7.60 (d, *J* = 7.7 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.32–7.28 (m, 3H), 7.18 (t, *J* = 7.4 Hz, 1H), 7.01 (d, *J* = 8.6 Hz, 2H), 4.88 (t, *J* = 7.3 Hz, 2H), 4.45–4.41 (m, 2H), 3.85 (s, 3H), 3.32 (t, *J* = 7.9 Hz, 2H), 1.46 (t, *J* = 7.1 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ = 163.8, 161.9, 159.5, 159.0, 137.5, 128.2, 127.0, 125.5, 125.1, 124.5, 124.2, 124.0, 121.3, 120.7, 120.0, 119.3, 114.3, 113.9, 112.0, 111.1, 61.6, 55.4, 44.8, 20.9, 14.1; HRMS (ESI-TOF) *m/z* calculated for C<sub>26</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup> 456.1559, found 456.1564.

**Ethyl 2-(4-fluoro)phenyl-1,3-dioxo-1,2,3,6,7,12-hexahydropyrrolo[3',4':1,2]indolizino[8,7-b]indole-4-carboxylate (5e).** Yellow solid (318 mg, 72%); m.p. 259–260 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.04 (s, 1H), 7.60 (d, *J* = 7.9 Hz, 1H), 7.44–7.38 (m, 3H), 7.30 (t, *J* = 7.3 Hz, 1H), 7.18 (t, *J* = 8.3 Hz, 3H), 4.88 (t, *J* = 7.1 Hz, 2H), 4.45–4.43 (m, 2H), 3.31 (t, *J* = 7.3 Hz, 2H), 1.47 (t, *J* = 7.0 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ = 163.5, 162.7, 161.4, 159.4, 137.6, 128.7, 128.6, 125.5, 124.6, 124.1, 123.7, 120.8, 120.2, 119.4, 116.0, 115.8, 113.7, 112.0, 111.3, 61.7, 44.8, 20.8, 14.1; HRMS (ESI-TOF) *m/z* calculated for C<sub>25</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 444.1359, found 444.1359.

**tert-Butyl 9,14-dioxo-5,9,14,15-tetrahydro-6H-naphtho[2',3':1,2]indolizino[8,7-b]indole-8-carboxylate (5f).** Red solid (275 mg, 63%); m.p. 199–200 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 11.26 (s, 1H), 8.28 (d, *J* = 8.8 Hz, 1H), 8.23 (d, *J* = 8.8 Hz, 1H), 7.73–7.69 (m, 2H), 7.56 (d, *J* = 7.9 Hz, 1H), 7.52 (d, *J* = 8.2 Hz, 1H), 7.28 (t, *J* = 7.7 Hz, 1H), 7.15 (t, *J* = 7.6 Hz, 1H), 4.48 (t, *J* = 7.4 Hz, 2H), 3.29 (t, *J* = 7.3 Hz, 2H), 1.72 (s, 9H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ = 180.5, 178.3, 160.2, 136.4, 135.7, 134.7, 133.3, 132.9, 131.1, 128.7, 127.1, 126.6, 125.6, 125.0, 124.2, 121.3, 120.3, 118.9, 115.1, 112.3, 110.5, 84.1, 44.3, 28.0, 20.4; HRMS (ESI-TOF) *m/z* calculated for C<sub>27</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 439.1657, found 439.1653.

**Ethyl 7,12-dioxo-7,12-dihydrobenzo[5,6]isoindolo[2,1-*a*]quinoline-13-carboxylate (7d).** Yellow solid (324 mg, 88%); m.p. 179–180 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.42 (d, *J* = 9.3 Hz, 1H), 8.30 (d, *J* = 7.6 Hz, 1H), 8.26–8.19 (m, 1H), 7.94 (d, *J* = 8.5 Hz, 1H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.78–7.69 (m, 2H), 7.62 (t, *J* = 7.6 Hz, 2H), 7.54 (t, *J* = 7.7 Hz, 1H), 4.75–4.70 (m, 2H), 1.55 (t, *J* = 7.1 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ = 180.5, 179.5, 163.8, 135.9, 134.8, 134.0, 133.7, 132.9, 132.6, 129.6, 129.6, 128.4, 126.9, 126.7, 126.4, 125.8, 123.6, 121.3, 118.6, 116.6, 111.9, 63.3, 13.9; HRMS (ESI-TOF) *m/z* calculated for C<sub>23</sub>H<sub>25</sub>NO<sub>4</sub> [M + H]<sup>+</sup> 370.1079, found 370.1083.

## Conclusions

In summary, we have developed an environmental friendly tandem [3 + 2]cycloaddition/oxidation/aromatization sequence of tetrahydroisoquinoline and tetrahydro-β-carboline acetates in a green solvent. This novel protocol provides a rapid and efficient access to biologically important pyrrolo[2,1-*a*]isoquinolines and indolizino[8,7-*b*]indoles in a highly concise fashion. Furthermore, for the first time, key intermediates related to proposed mechanism of this tandem reaction were identified and characterized by online monitoring of reactions through ESI-MS(/MS) experiments. With TBHP as the “green”

oxidant, cheap, low toxic TBAI as the catalyst, and isopropanol as the green solvent, this protocol would be more attractive in the field of green chemistry.

## Acknowledgements

SN, NPK, and PS are thankful to DoP, Ministry of Chemicals and Fertilizers Govt. of India, New Delhi for the award of Research Fellowship. FMN and LSS acknowledge InnovaChile CORFO Code FCR-CSB09CEII-6991 and Anillo Científico FONDECYT ACT-1107 for supporting this research activity. FMN thanks FONDECYT-Iniciación (11130086). LSS thanks additional support from PIEI (Química y Bio-organica en Recursos Naturales) Universidad de Talca.

## Notes and references

- (a) H. Fan, J. Peng, M. T. Hamann and J. F. Hu, *Chem. Rev.*, 2007, **108**, 264–287; (b) D. Pla, F. Albericio and M. Alvarez, *MedChemComm*, 2011, **2**, 689–697; (c) B. T. Fukuda, F. Ishibashi and M. Iwaob, *Heterocycles*, 2011, **83**, 491–529; (d) S. T. Handy and Y. Zhang, *Org. Prep. Proced. Int.*, 2005, **37**, 411–445; (e) F. A. M. A. D. Pla, *Anti-Cancer Agents Med. Chem.*, 2008, **2008**, 746–760.
- (a) D. M. Roll, C. M. Ireland, H. S. M. Lu and J. Clardy, *J. Org. Chem.*, 1988, **53**, 3276–3278; (b) N. L. Segraves, S. J. Robinson, D. Garcia, S. A. Said, X. Fu, F. J. Schmitz, H. Pietraszkiewicz, F. A. Valeriote and P. J. Crews, *J. Nat. Prod.*, 2004, **67**, 783–792; (c) T. S. Kam and K. M. Sim, *Phytochemistry*, 1998, **47**, 145–147; (d) A. M. Popov and V. A. Stonik, *Antibiot. Khimioter.*, 1991, **36**, 12–14; (e) A. Hormann, B. Chaudhuri and H. Fretz, *Bioorg. Med. Chem.*, 2001, **9**, 917–921; (f) D. R. Herbert, *German Patent* 2,033,631, 1971Chemical abstracts, 1972, 76, 113061h.
- (a) C. Yu, Y. Zhang, S. Zhang, H. Li and W. Wang, *Chem. Commun.*, 2011, **47**, 1036–1038; (b) Y. Q. Zou, L. Q. Lu, L. Fu, N. J. Chang, J. Rong, J. R. Chen and W.-J. Xiao, *Angew. Chem., Int. Ed.*, 2011, **50**, 7171–7175; (c) M. Rueping, D. Leonori and T. Poisson, *Chem. Commun.*, 2011, **47**, 9615–9617; (d) L. Huang and J. Zhao, *Chem. Commun.*, 2013, **49**, 3751–3753; (e) S. Guo, H. Zhang, L. Huang, Z. Guo, G. Xiong and J. Zhao, *Chem. Commun.*, 2013, **49**, 8689–8691; (f) H. M. Huang, Y. J. Li, Q. Ye, W. B. Yu, L. Han, J. H. Jia and J. R. Gao, *J. Org. Chem.*, 2014, **79**, 1084–1092; (g) H. M. Huang, F. Huang, Y. J. Li, J. H. Jia, Q. Ye, L. Han and J. R. Gao, *RSC Adv.*, 2014, **4**, 27250–27258.
- (a) M. Jida, O. M. Soueidan, B. Deprez, G. Lacondea and R. Deprez-Poulain, *Green Chem.*, 2012, **14**, 909–911; (b) Z. S. Nurmaganbetov, E. E. Shultz, S. V. Chernov, A. Z. Turmukhambetov, R. B. Seydakhmetova, M. M. Shakirov, G. A. Tolstikov and S. M. Adekenov, *Chem. Heterocycl. Compd.*, 2011, **46**, 1494–1499; (c) H. Waldmann, L. Eberhardt, K. Wittstein and K. Kumar, *Chem. Commun.*, 2010, **46**, 4622–4624; (d) S. U. Dighe, S. Hutait and S. Batra, *ACS Comb. Sci.*, 2012, **14**, 665–672.
- X. F. Wu, J. L. Gong and X. Qi, *Org. Biomol. Chem.*, 2014, **12**, 5807–5817.

- 6 (a) W. A. Silva, M. T. Rodrigues, N. Shankaraiah, R. B. Ferreira, C. K. Z. Andrade, R. A. Pilli and L. S. Santos, *Org. Lett.*, 2009, **11**, 3238–3241; (b) A. Kamal, M. Sathish, V. L. Nayak, V. Srinivasulu, B. Kavitha, Y. Tangella, D. Thummuri, C. Bagul, N. Shankaraiah and N. Nagesh, *Bioorg. Med. Chem.*, 2015, **23**, 5511–5526; (c) N. Shankaraiah, K. P. Siraj, S. Nekkanti, V. Srinivasulu, M. Satish, P. Sharma, K. R. Senwar, M. V. P. S. Vishnuvardhan, S. Ramakrishna and A. Kamal, *Bioorg. Chem.*, 2015, **59**, 130–139; (d) N. Shankaraiah, S. Nekkanti, K. J. Chudasama, K. R. Senwar, P. Sharma, M. K. Jeengar, V. G. M. Naidu, V. Srinivasulu and A. Kamal, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 5413–5417; (e) A. Kamal, V. Srinivasulu, V. L. Nayak, M. Sathish, N. Shankaraiah, C. Bagul, N. V. S. Reddy, N. Rangaraj and N. Nagesh, *ChemMedChem*, 2014, **9**, 2084–2098; (f) A. Kamal, M. K. Reddy, T. S. Reddy, L. S. Santos and N. Shankaraiah, *Synlett*, 2011, 61–64.
- 7 (a) J. Barluenga, M. Marco-Arias, F. Gonzalez-Bobes, A. Ballesteros and J. M. Gonzalez, *Chem. Commun.*, 2004, 2616–2617; (b) T. Nobuta, N. Tada, A. Fujiya, A. Kariya, T. Miura and A. Itoh, *Org. Lett.*, 2013, **15**, 574–577; (c) H.-M. Huang, F. Huang, Y.-J. Li, J.-H. Jia, Q. Ye, L. Hana and J.-R. Gao, *RSC Adv.*, 2014, **4**, 27250–27258.
- 8 (a) L. S. Santos and J. O. Metzger, *Angew. Chem., Int. Ed.*, 2006, **45**, 977–981; (b) L. S. Santos, L. Knaack and J. O. Metzger, *Int. J. Mass Spectrom.*, 2005, **246**, 84–104; (c) B. A. DaSilveira, L. S. Santos, F. M. Nachtigall, M. N. Eberlin and J. Dupont, *Angew. Chem., Int. Ed.*, 2006, **45**, 7251–7254.
- 9 (a) N. Shankaraiah, N. Markandeya, V. Srinivasulu, K. Sreekanth, C. S. Reddy, L. S. Santos and A. Kamal, *J. Org. Chem.*, 2011, **76**, 7017–7026; (b) A. Kamal, N. Markandeya, N. Shankaraiah, C. R. Reddy, S. Prabhakar, C. S. Reddy, M. N. Eberlin and L. S. Santos, *Chem.–Eur. J.*, 2009, **15**, 7215–7224; (c) L. S. Santos, *Eur. J. Org. Chem.*, 2008, 235–253; (d) L. S. Santos, in *Reactive intermediates: MS investigations in solution*, Wiley-VCH, Weinheim, 2012.
- 10 K. L. Vikse, M. P. Woods and J. S. McIndoe, *Organometallics*, 2010, **29**, 6615–6618.